MUC1 and neoplasm: The construct design was based on the rationale, that by simultaneous binding to TA-MUC1, higher IL-15 doses could be applied to accumulate in the tumor, without leading to lymphocyte exhaustion and reduced responsiveness after multiple treatments as described for IL-15 superagonists [15].